Login to Your Account



Portola shares gain as company details betrixaban trial design

By Michael Fitzhugh
Staff Writer

Monday, April 14, 2014
Portola Pharmaceuticals Inc.'s shares (NASDAQ:PTLA) rose 6.4 percent Monday as the company advanced its global pivotal trial of betrixaban, testing how well the drug prevents blood clots when patients are hospitalized for critical cardiovascular conditions and following their release.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription